Long-term survival after liver transplantation in hepatocellular carcinoma patients: a single-center experience
10.3760/cma.j.cn113855-20230314-00122
- VernacularTitle:单中心肝细胞癌患者肝移植术后长期生存情况分析
- Author:
Yanbin NI
1
;
Guangming LI
;
Fushun WANG
;
Xisheng LENG
;
Jiye ZHU
Author Information
1. 北京大学人民医院肝胆外科，北京 100044
- Keywords:
Carcinoma,hepatocellular;
Liver transplantation;
Survival analysis
- From:
Chinese Journal of General Surgery
2023;38(9):641-647
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the long-term cumulative survival and tumor-free survival of hepatocellular carcinoma (HCC) patients after liver transplantation, as well as the influencing factors.Methods:We conducted a retrospective study on 228 HCC patients receiving liver transplantation from May 1, 2000 to May 1, 2012 at the Department of Hepatobiliary Surgery, Peking University People's Hospital. A total of 166 patients met the recruit criteria. The patients' perioperative data and follow-up data were collected. We analyzed the cumulative survival and tumor-free survival of the recipients, as well as the influencing factors.Results:The 1-, 5- and 10-year cumulative survival of the 166 HCC patients were 80.7%, 52.4% and 45.8%, respectively, while the 1-, 5- and 10-year tumor-free survival of these patients were 60.2%, 47.6% and 44.0%, respectively. Among these patients,a total of 96 recipients met the University of California, San Francisco (UCSF) criteria, whose 1-, 5- and 10-year cumulative survival were 83.3%, 66.7%, and 59.4%, respectively, and tumor-free survival were 74.0%, 62.5% and 57.3%, respectively. Multivariate analysis showed that beyond the UCSF criteria, alpha fetoprotein (AFP) ≥ 400 ng/ml before transplantation and poorly differentiated carcinoma were independent factors affecting cumulative survival and tumor-free survival ( P < 0.05). Conclusions:Liver transplantation is an effective treatment of HCC. Besides the size and the number of the tumors, AFP ≥ 400 ng/ml before transplantation and poorly differentiated tumors are independent factors affecting the long-term cumulative survival and tumor-free survival of HCC patients.
